Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

PhaseBio Pharmaceuticals Inc. (PHAS)

3.51   0.03 (0.86%) 09-30 18:11
Open: 3.51 Pre. Close: 3.48
High: 3.54 Low: 3.32
Volume: 121,651 Market Cap: 103M
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 32 full-time employees. The firm is focused on the development and commercialization of therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The Company’s lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor, which the Company is developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. Its product candidate, PB1046, is a once-weekly fusion protein for the treatment of pulmonary arterial hypertension, or PAH. PB1046 utilizes its proprietary elastin-like polypeptide (ELP), technology, which also serves as the engine for its preclinical pipeline. Its ELP biopolymer technology utilizes a mechanism of slow absorption through a reversible phase transition and a prolonged circulatory half-life.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.513 - 3.538 3.538 - 3.557
Low: 3.295 - 3.32 3.32 - 3.34
Close: 3.466 - 3.506 3.506 - 3.538

Technical analysis

as of: 2020-09-30 4:45:16 PM
Overall:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 4.29     One year: 4.75
Support: Support1: 3.03    Support2: 2.52
Resistance: Resistance1: 3.67    Resistance2: 4.07
Pivot: 3.39
Moving Average: MA(5): 3.35     MA(20): 3.41
MA(100): 4.34     MA(250): 4.29
MACD: MACD(12,26): -0.13     Signal(9): -0.16
Stochastic oscillator: %K(14,3): 58.33     %D(3): 46.07
RSI: RSI(14): 48.32
52-week: High: 8.49  Low: 2.60  Change(%): -13.2
Average Vol(K): 3-Month: 42974  10-Days: 17026

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
PHAS has closed below upper band by 30.3%. Bollinger Bands are 55.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to PHAS's normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Thu, 10 Sep 2020
Do Analysts Expect PhaseBio Pharmaceuticals Inc (PHAS) Stock to Rise? - InvestorsObserver

Wed, 09 Sep 2020
PhaseBio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference - Odessa American

Fri, 14 Aug 2020
Here is why PhaseBio Pharmaceuticals Inc. (PHAS) recent weekly performance of -2.83% shouldn’t bother you at All - The InvestChronicle

Mon, 20 Jul 2020
The PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) Analysts Have Been Trimming Their Sales Forecasts - Simply Wall St

Wed, 17 Jun 2020
What Kind Of Shareholder Appears On The PhaseBio Pharmaceuticals, Inc.’s (NASDAQ:PHAS) Shareholder Register? - Simply Wall St

Mon, 15 Jun 2020
Hedge Funds Are Selling PhaseBio Pharmaceuticals, Inc. (PHAS) - Yahoo Finance

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 29
Shares Float (M) 15
% Held by Insiders 14.28
% Held by Institutions 77.91
Shares Short (K) 3,720
Shares Short P. Month (K) 3,680

Stock Financials

EPS -2.286
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 0.910
Profit Margin
Operating Margin -4623.09
Return on Assets (ttm) -45.5
Return on Equity (ttm) -121.8
Qtrly Rev. Growth
Gross Profit (p.s.) -0.973
Sales Per Share 0.045
EBITDA (p.s.) -2.081
Qtrly Earnings Growth
Operating Cash Flow (M) -54
Levered Free Cash Flow (M) -37

Stock Valuations

PE Ratio -1.53
PEG Ratio
Price to Book value 3.85
Price to Sales 77.79
Price to Cash Flow -1.92

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.